US
CA
NZ
UK
AU
IND
Last update at 2025-06-13T14:12:00Z
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
Adagene Reports Full Year 2024 Financial Results and Provides Corporate Update
Mon 24 Mar 25, 12:00 PMAdagene to Present at 11th Annual Immuno-Oncology 360⁰ Summit
Thu 13 Mar 25, 12:00 PM| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Income before tax | -79.51279M | -71.47632M | -16.43231M | -16.43231M | -15.26618M |
| Minority interest | - | - | - | - | - |
| Net income | -79.97185M | -73.17794M | -16.43547M | -17.29388M | -14.71918M |
| Selling general administrative | 11.87M | 14.44M | 3.44M | 3.44M | 2.77M |
| Selling and marketing expenses | - | - | - | - | - |
| Gross profit | 9.29M | 10.18M | 0.48M | 0.48M | 1.51M |
| Reconciled depreciation | 1.45M | 1.13M | 0.86M | 0.82M | 0.91M |
| Ebit | -83.92068M | -72.36409M | -19.16965M | -19.16965M | -17.33453M |
| Ebitda | -81.37479M | -70.50910M | -17.52349M | -16.70681M | -14.81310M |
| Depreciation and amortization | 2.55M | 1.85M | 1.65M | 2.46M | 2.52M |
| Non operating income net other | - | - | - | - | - |
| Operating income | -83.92068M | -72.36409M | -19.16965M | -19.16965M | -17.33453M |
| Other operating expenses | 93.21M | 82.54M | 19.65M | 19.65M | 18.85M |
| Interest expense | 0.69M | 0.36M | 0.14M | 0.14M | 0.09M |
| Tax provision | 0.46M | 1.70M | 0.00000M | 0.00000M | 0.00000M |
| Interest income | 0.38M | 0.08M | 0.92M | 0.92M | 0.71M |
| Net interest income | -0.31582M | -0.28760M | 0.78M | 0.78M | 0.62M |
| Extraordinary items | - | - | - | - | - |
| Non recurring | - | - | - | - | - |
| Other items | - | - | - | - | - |
| Income tax expense | 0.46M | 1.70M | 0.00316M | 0.86M | -0.54700M |
| Total revenue | 9.29M | 10.18M | 0.48M | 0.48M | 1.51M |
| Total operating expenses | 93.21M | 82.54M | 19.65M | 19.65M | 18.85M |
| Cost of revenue | - | - | - | - | - |
| Total other income expense net | 4.41M | 0.89M | 2.74M | 2.74M | 2.07M |
| Discontinued operations | - | - | - | - | - |
| Net income from continuing ops | -79.97185M | -73.17794M | -16.43231M | -16.43231M | -15.26618M |
| Net income applicable to common shares | - | -73.20649M | -42.64539M | -16.67849M | -14.30284M |
| Preferred stock and other adjustments | - | - | - | - | - |
| Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total assets | 115.73M | 152.40M | 189.51M | 84.26M | 105.89M |
| Intangible assets | - | - | - | - | - |
| Earning assets | - | - | - | - | - |
| Other current assets | 3.29M | 4.94M | 4.06M | 3.81M | 1.25M |
| Total liab | 45.17M | 69.31M | 32.95M | 173.65M | 162.90M |
| Total stockholder equity | 70.56M | 83.09M | 156.56M | -89.38996M | -57.00895M |
| Deferred long term liab | - | - | - | - | - |
| Other current liab | 19.72M | 22.54M | 16.50M | 8.59M | 4.44M |
| Common stock | 0.00555M | 0.00550M | 0.00563M | 0.00189M | 0.00152M |
| Capital stock | 0.00555M | 0.00550M | 0.00563M | 0.00189M | 0.00152M |
| Retained earnings | -277.75148M | -258.80511M | -178.83326M | -105.65532M | -63.25805M |
| Other liab | - | 0.03M | 0.14M | 0.09M | - |
| Good will | - | - | - | - | - |
| Other assets | 0.00000M | 0.11M | 0.07M | 3.10M | 0.09M |
| Cash | 109.93M | 143.76M | 174.39M | 75.15M | 92.53M |
| Cash and equivalents | - | - | - | - | - |
| Total current liabilities | 31.46M | 55.08M | 29.82M | 16.15M | 7.18M |
| Current deferred revenue | 0.05M | 15.11M | 5.50M | 0.73M | 0.99M |
| Net debt | -87.62739M | -115.78745M | -166.90187M | -67.17003M | -89.97767M |
| Short term debt | 8.59M | 13.77M | 4.50M | 5.02M | 1.04M |
| Short long term debt | 8.40M | 13.62M | 4.50M | 5.02M | 1.04M |
| Short long term debt total | 22.31M | 27.97M | 7.49M | 7.98M | 2.56M |
| Other stockholder equity | 350.11M | 342.74M | 335.48M | 16.61M | 6.59M |
| Property plant equipment | - | 2.97M | 3.49M | 2.07M | 1.88M |
| Total current assets | 113.44M | 149.32M | 185.95M | 79.10M | 103.92M |
| Long term investments | - | - | - | - | - |
| Net tangible assets | - | 83.09M | 156.56M | -89.38996M | -57.00895M |
| Short term investments | - | - | - | 0.00000M | 8.00M |
| Net receivables | 0.22M | 0.62M | 7.51M | 0.13M | 2.14M |
| Long term debt | 13.54M | 14.15M | 2.99M | 2.97M | 1.52M |
| Inventory | - | - | - | - | - |
| Accounts payable | 3.09M | 3.67M | 3.32M | 1.81M | 0.71M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | - | - | - | - | - |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | -1.80009M | -0.84930M | -0.09398M | -0.35098M | -0.34489M |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | - | - | - | 0.00189M | 0.00152M |
| Preferred stock total equity | - | - | - | - | - |
| Retained earnings total equity | - | - | - | - | - |
| Treasury stock | - | - | - | - | - |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | 0.08M | 0.11M | 0.07M | 3.10M | 0.09M |
| Deferred long term asset charges | - | - | - | - | - |
| Non current assets total | 2.29M | 3.08M | 3.56M | 5.17M | 1.97M |
| Capital lease obligations | 0.37M | 0.21M | - | - | - |
| Long term debt total | - | - | - | - | - |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Investments | -0.68605M | -2.50993M | 8.00M | 25.00M | -29.00000M |
| Change to liabilities | 0.00000M | 6.33M | 0.83M | 1.15M | 0.39M |
| Total cashflows from investing activities | - | -2.50993M | 7.07M | 24.86M | -29.50954M |
| Net borrowings | - | -0.70286M | 5.02M | 0.23M | 1.06M |
| Total cash from financing activities | 17.82M | 145.36M | 4.44M | 69.69M | 51.06M |
| Change to operating activities | - | 4.36M | 0.93M | -2.58564M | 0.12M |
| Net income | -79.97185M | -73.17794M | -42.39728M | -16.43231M | -15.26618M |
| Change in cash | -30.63256M | 99.24M | -17.38179M | 76.47M | 7.32M |
| Begin period cash flow | 174.39M | 75.15M | 92.53M | 16.06M | 8.74M |
| End period cash flow | 143.76M | 174.39M | 75.15M | 92.53M | 16.06M |
| Total cash from operating activities | -48.61169M | -43.41462M | -28.52972M | -18.15356M | -14.26467M |
| Issuance of capital stock | 0.00000M | 149.79M | 0.00000M | 69.00M | 50.00M |
| Depreciation | 1.45M | 1.13M | 0.86M | 0.82M | 0.91M |
| Other cashflows from investing activities | - | - | - | - | - |
| Dividends paid | - | 4.61M | - | - | - |
| Change to inventory | - | 6.02M | 0.93M | -2.58564M | - |
| Change to account receivables | 3.00M | -3.00000M | 0.48M | -0.48000M | -0.48000M |
| Sale purchase of stock | -3.97668M | -2.36158M | - | - | - |
| Other cashflows from financing activities | 26.15M | 7.63M | 5.50M | 72.11M | 52.42M |
| Change to netincome | - | 19.29M | 10.77M | -0.61941M | -0.42131M |
| Capital expenditures | 0.69M | 2.51M | 0.94M | 0.15M | 0.51M |
| Change receivables | - | - | - | - | - |
| Cash flows other operating | - | - | - | - | - |
| Exchange rate changes | - | - | - | - | - |
| Cash and cash equivalents changes | - | - | - | - | - |
| Change in working capital | 21.94M | 9.35M | 2.23M | -1.91852M | 0.51M |
| Stock based compensation | 10.52M | 18.68M | 10.13M | 0.61M | 0.13M |
| Other non cash items | -2.54851M | -0.00995M | 0.65M | -1.23112M | -0.54785M |
| Free cash flow | -49.30262M | -45.92455M | -29.46492M | -18.30539M | -14.77937M |
Sector: Healthcare Industry: Biotechnology
| Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| ADAG Adagene Inc |
-0.015 0.77% | 1.95 | - | - | 109.63 | 1.61 | 20.00 | 1.12 |
| NVO Novo Nordisk A/S |
-0.56 0.69% | 80.49 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
| NONOF Novo Nordisk A/S |
-0.41 0.51% | 80.59 | 41.06 | 31.25 | 2.08 | 33.11 | 2.11 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
-1.29 0.28% | 458.77 | 29.67 | 24.33 | 10.38 | 5.83 | 9.33 | 20.00 |
| REGN Regeneron Pharmaceuticals Inc |
2.82 0.54% | 524.66 | 29.07 | 20.12 | 7.57 | 3.82 | 6.95 | 19.42 |
Adagene Inc., a clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers. The company's product candidates include ADG106, a human ligand-blocking agonistic anti- CD137 IgG4 monoclonal antibodies (mAbs) that is in Phase 1b/2 clinical trials for the treatment advanced solid tumors and non-Hodgkin's lymphoma; ADG126, a masked fully-human anti-CTLA-4 mAb that is in Phase 1 clinical trial for the treatment advanced/metastatic solid tumors; and ADG116, a human ligand-blocking anti-CTLA-4 mAb, which is in Phase 1b/2 clinical development for the treatment of advanced/metastatic solid tumors. It also offers ADG104, an anti-PD-L1 mAb that is in Phase 2 clinical development; ADG125, a novel anti-CSF-1R mAb, which is in Phase I clinical trial; ADG206, a masked, Fc engineered anti-CD137 agonistic POWERbody; ADG153, a masked anti-CD47 IgG1 SAFEbody, which is in preclinical for the treatment hematologic and solid tumors; ADG138, novel HER2xCD3 POWERbody, which is in preclinical for the treatment HER2-expressing solid tumors; and ADG152, a v POWERbody, which is in preclinical stage for the treatment off-tumor toxicities, as well as develops anti-CD28 bispecific POWERbody TCEs. The company was incorporated in 2011 and is headquartered in Suzhou, China.
Building C14, Suzhou, China, 215123
| Name | Title | Year Born |
|---|---|---|
| Dr. Peter P. Luo Ph.D. | Co-Founder, CEO & Chairman | 1966 |
| Mr. Man Kin Tam M.B.A. | CFO & Director | 1977 |
| Dr. Fangyong Du Ph.D. | Chief Technology Officer | 1970 |
| Dr. Jc Xu M.D., Ph.D. | Chief Scientific Officer | 1965 |
| Ms. Ami Celeste Knoefler | VP of Investor Relations & Corp. Communications | NA |
| Ms. Ling Zhou | Head of HR | NA |
| Dr. Qinghai Zhao | Chief Manufacturing Officer | 1961 |
| Ms. Yan Li M.B.A. | Sr. VP of Bioinformatics & Information Technology | 1975 |
| Ms. Xiaohong She | Sr. VP & Head of Clinical Operations | 1967 |
| Dr. Guizhong Liu Ph.D. | Head of Biology & Pharmacology | 1971 |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes. This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API. Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...